Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernand Labrie

Showing results (181-190 of 204) with videos related to

Pageof 21
Sort By:
The Journal of Sexual Medicine|April 30, 2014
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal womenFernand Labrie, David Archer, Céline Bouchard, et al.
The Journal of Sexual Medicine|November 25, 2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal AtrophyFernand Labrie, Leonard Derogatis, David F Archer, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|May 13, 2010
High internal consistency and efficacy of intravaginal DHEA for vaginal atrophyFernand Labrie, David Archer, Céline Bouchard, et al.
Menopause (New York, N.Y.)|May 14, 2009
Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophyFernand Labrie, David Archer, Céline Bouchard, et al.
Menopause (New York, N.Y.)|May 9, 2009
Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal womenFernand Labrie, David Archer, Céline Bouchard, et al.
The Journal of Clinical Endocrinology and Metabolism|June 24, 2011
Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohortsShalender Bhasin, Michael Pencina, Guneet Kaur Jasuja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancerFernand Labrie, Pierre Champagne, Claude Labrie, et al.
The Journal of Clinical Endocrinology and Metabolism|September 24, 2016
Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair LossShehzad Basaria, Ravi Jasuja, Grace Huang, et al.
Menopause (New York, N.Y.)|May 14, 2009
Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administrationFernand Labrie, David Archer, Céline Bouchard, et al.
Maturitas|March 16, 2015
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label studyFernand Labrie, David F Archer, Céline Bouchard, et al.
Pageof 21

Showing results (181-190 of 204) with videos related to

Sort By:
Pageof 21
The Journal of Sexual Medicine|April 30, 2014
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal womenFernand Labrie, David Archer, Céline Bouchard, et al.
The Journal of Sexual Medicine|November 25, 2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal AtrophyFernand Labrie, Leonard Derogatis, David F Archer, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|May 13, 2010
High internal consistency and efficacy of intravaginal DHEA for vaginal atrophyFernand Labrie, David Archer, Céline Bouchard, et al.
Menopause (New York, N.Y.)|May 14, 2009
Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophyFernand Labrie, David Archer, Céline Bouchard, et al.
Menopause (New York, N.Y.)|May 9, 2009
Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal womenFernand Labrie, David Archer, Céline Bouchard, et al.
The Journal of Clinical Endocrinology and Metabolism|June 24, 2011
Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohortsShalender Bhasin, Michael Pencina, Guneet Kaur Jasuja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancerFernand Labrie, Pierre Champagne, Claude Labrie, et al.
The Journal of Clinical Endocrinology and Metabolism|September 24, 2016
Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair LossShehzad Basaria, Ravi Jasuja, Grace Huang, et al.
Menopause (New York, N.Y.)|May 14, 2009
Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administrationFernand Labrie, David Archer, Céline Bouchard, et al.
Maturitas|March 16, 2015
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label studyFernand Labrie, David F Archer, Céline Bouchard, et al.
Pageof 21